Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Correction to: Ibrutinib does not prolong the corrected QT interval in healthy subjects: results from a thorough QT study.

de Jong J, Hellemans P, Jiao JJ, Huang Y, Mesens S, Sukbuntherng J, Ouellet D.

Cancer Chemother Pharmacol. 2018 Feb;81(2):423. doi: 10.1007/s00280-017-3490-7.

PMID:
29214363
2.

Ibrutinib does not prolong the corrected QT interval in healthy subjects: results from a thorough QT study.

de Jong J, Hellemans P, Jiao JJ, Huang Y, Mesens S, Sukbuntherng J, Ouellet D.

Cancer Chemother Pharmacol. 2017 Dec;80(6):1227-1237. doi: 10.1007/s00280-017-3471-x. Epub 2017 Oct 28. Erratum in: Cancer Chemother Pharmacol. 2017 Dec 6;:.

PMID:
29080970
3.

Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL.

Barr PM, Brown JR, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre S, Mulligan SP, Jaeger U, Furman RR, Cymbalista F, Montillo M, Dearden C, Robak T, Moreno C, Pagel JM, Burger JA, Suzuki S, Sukbuntherng J, Cole G, James DF, Byrd JC.

Blood. 2017 May 11;129(19):2612-2615. doi: 10.1182/blood-2016-12-737346. Epub 2017 Apr 3.

4.

Ibrutinib Inhibits ERBB Receptor Tyrosine Kinases and HER2-Amplified Breast Cancer Cell Growth.

Chen J, Kinoshita T, Sukbuntherng J, Chang BY, Elias L.

Mol Cancer Ther. 2016 Dec;15(12):2835-2844. Epub 2016 Sep 27.

5.

Ibrutinib Dosing Strategies Based on Interaction Potential of CYP3A4 Perpetrators Using Physiologically Based Pharmacokinetic Modeling.

de Zwart L, Snoeys J, De Jong J, Sukbuntherng J, Mannaert E, Monshouwer M.

Clin Pharmacol Ther. 2016 Nov;100(5):548-557. doi: 10.1002/cpt.419. Epub 2016 Aug 27.

PMID:
27367453
6.

Single-dose pharmacokinetics of ibrutinib in subjects with varying degrees of hepatic impairment<sup/>.

de Jong J, Skee D, Hellemans P, Jiao J, de Vries R, Swerts D, Lawitz E, Marbury T, Smith W, Sukbuntherng J, Mannaert E.

Leuk Lymphoma. 2017 Jan;58(1):185-194. Epub 2016 Jun 7.

PMID:
27267254
7.

Bioanalysis of ibrutinib and its active metabolite in human plasma: selectivity issue, impact assessment and resolution.

de Vries R, Huang M, Bode N, Jejurkar P, Jong Jd, Sukbuntherng J, Sips L, Weng N, Timmerman P, Verhaeghe T.

Bioanalysis. 2015;7(20):2713-24. doi: 10.4155/bio.15.159. Epub 2015 Oct 28.

PMID:
26507928
8.

Stable isotope-labelled intravenous microdose for absolute bioavailability and effect of grapefruit juice on ibrutinib in healthy adults.

de Vries R, Smit JW, Hellemans P, Jiao J, Murphy J, Skee D, Snoeys J, Sukbuntherng J, Vliegen M, de Zwart L, Mannaert E, de Jong J.

Br J Clin Pharmacol. 2016 Feb;81(2):235-45. doi: 10.1111/bcp.12787. Epub 2016 Jan 15.

9.

Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants.

de Jong J, Skee D, Murphy J, Sukbuntherng J, Hellemans P, Smit J, de Vries R, Jiao JJ, Snoeys J, Mannaert E.

Pharmacol Res Perspect. 2015 Aug;3(4):e00156. doi: 10.1002/prp2.156. Epub 2015 Jun 24.

10.

The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia.

de Jong J, Sukbuntherng J, Skee D, Murphy J, O'Brien S, Byrd JC, James D, Hellemans P, Loury DJ, Jiao J, Chauhan V, Mannaert E.

Cancer Chemother Pharmacol. 2015 May;75(5):907-16. doi: 10.1007/s00280-015-2708-9. Epub 2015 Feb 28.

11.

Absorption, metabolism, and excretion of oral ¹⁴C radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men.

Scheers E, Leclercq L, de Jong J, Bode N, Bockx M, Laenen A, Cuyckens F, Skee D, Murphy J, Sukbuntherng J, Mannens G.

Drug Metab Dispos. 2015 Feb;43(2):289-97. doi: 10.1124/dmd.114.060061. Epub 2014 Dec 8.

12.

Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies.

Marostica E, Sukbuntherng J, Loury D, de Jong J, de Trixhe XW, Vermeulen A, De Nicolao G, O'Brien S, Byrd JC, Advani R, McGreivy J, Poggesi I.

Cancer Chemother Pharmacol. 2015 Jan;75(1):111-21. doi: 10.1007/s00280-014-2617-3. Epub 2014 Nov 8.

PMID:
25381051
13.

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.

Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, Grant B, Sharman JP, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Sukbuntherng J, Chang BY, Clow F, Hedrick E, Buggy JJ, James DF, O'Brien S.

N Engl J Med. 2013 Jul 4;369(1):32-42. doi: 10.1056/NEJMoa1215637. Epub 2013 Jun 19. Erratum in: N Engl J Med. 2014 Feb 20;370(8):786.

14.

Population pharmacokinetics and pharmacodynamics of gabapentin after administration of gabapentin enacarbil.

Lal R, Sukbuntherng J, Luo W, Tovera J, Lassauzet ML, Cundy KC.

J Clin Pharmacol. 2013 Jan;53(1):29-40. doi: 10.1177/0091270012439209. Epub 2013 Jan 24.

PMID:
23400741
15.

Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.

Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B, Kolibaba KS, Furman RR, Rodriguez S, Chang BY, Sukbuntherng J, Izumi R, Hamdy A, Hedrick E, Fowler NH.

J Clin Oncol. 2013 Jan 1;31(1):88-94. doi: 10.1200/JCO.2012.42.7906. Epub 2012 Oct 8.

16.

Clinical pharmacokinetics of gabapentin after administration of gabapentin enacarbil extended-release tablets in patients with varying degrees of renal function using data from an open-label, single-dose pharmacokinetic study.

Lal R, Sukbuntherng J, Luo W, Chen D, Blumenthal R, Ho J, Cundy KC.

Clin Ther. 2012 Jan;34(1):201-13. doi: 10.1016/j.clinthera.2011.12.004. Epub 2011 Dec 28.

PMID:
22206794
17.

A phase I, single-dose study of the disposition of 14C-radiolabeled gabapentin enacarbil in healthy male volunteers.

Lal R, Sukbuntherng J, Ho J, Cundy KC.

Int J Clin Pharmacol Ther. 2011 Feb;49(2):109-15.

PMID:
21255527
18.

Clinical pharmacokinetic drug interaction studies of gabapentin enacarbil, a novel transported prodrug of gabapentin, with naproxen and cimetidine.

Lal R, Sukbuntherng J, Luo W, Vicente V, Blumenthal R, Ho J, Cundy KC.

Br J Clin Pharmacol. 2010 May;69(5):498-507. doi: 10.1111/j.1365-2125.2010.03616.x.

19.

The effect of food with varying fat content on the clinical pharmacokinetics of gabapentin after oral administration of gabapentin enacarbil.

Lal R, Sukbuntherng J, Luo W, Huff FJ, Zou J, Cundy KC.

Int J Clin Pharmacol Ther. 2010 Feb;48(2):120-8.

PMID:
20137764
20.

Pharmacokinetics and tolerability of single escalating doses of gabapentin enacarbil: a randomized-sequence, double-blind, placebo-controlled crossover study in healthy volunteers.

Lal R, Sukbuntherng J, Luo W, Chen D, Vu A, Tovera J, Cundy KC.

Clin Ther. 2009 Aug;31(8):1776-86. doi: 10.1016/j.clinthera.2009.07.026.

PMID:
19808136
21.

Arbaclofen placarbil, a novel R-baclofen prodrug: improved absorption, distribution, metabolism, and elimination properties compared with R-baclofen.

Lal R, Sukbuntherng J, Tai EH, Upadhyay S, Yao F, Warren MS, Luo W, Bu L, Nguyen S, Zamora J, Peng G, Dias T, Bao Y, Ludwikow M, Phan T, Scheuerman RA, Yan H, Gao M, Wu QQ, Annamalai T, Raillard SP, Koller K, Gallop MA, Cundy KC.

J Pharmacol Exp Ther. 2009 Sep;330(3):911-21. doi: 10.1124/jpet.108.149773. Epub 2009 Jun 5.

22.

Evaluation of the safety and pharmacokinetics of the multi-targeted receptor tyrosine kinase inhibitor sunitinib during embryo-fetal development in rats and rabbits.

Patyna S, Haznedar J, Morris D, Freshwater K, Peng G, Sukbuntherng J, Chmielewski G, Matsumoto D.

Birth Defects Res B Dev Reprod Toxicol. 2009 Jun;86(3):204-13. doi: 10.1002/bdrb.20194.

PMID:
19294680
23.

Single- and multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in non-clinical species.

Haznedar JO, Patyna S, Bello CL, Peng GW, Speed W, Yu X, Zhang Q, Sukbuntherng J, Sweeny DJ, Antonian L, Wu EY.

Cancer Chemother Pharmacol. 2009 Sep;64(4):691-706. doi: 10.1007/s00280-008-0917-1. Epub 2009 Jan 25.

PMID:
19169880
24.

SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity.

Patyna S, Laird AD, Mendel DB, O'farrell AM, Liang C, Guan H, Vojkovsky T, Vasile S, Wang X, Chen J, Grazzini M, Yang CY, Haznedar JO, Sukbuntherng J, Zhong WZ, Cherrington JM, Hu-Lowe D.

Mol Cancer Ther. 2006 Jul;5(7):1774-82.

25.

Evaluation of antitumor properties of novel saframycin analogs in vitro and in vivo.

Spencer JR, Sendzik M, Oeh J, Sabbatini P, Dalrymple SA, Magill C, Kim HM, Zhang P, Squires N, Moss KG, Sukbuntherng J, Graupe D, Eksterowicz J, Young PR, Myers AG, Green MJ.

Bioorg Med Chem Lett. 2006 Sep 15;16(18):4884-8. Epub 2006 Jul 25.

PMID:
16870445
26.

Efforts toward oral bioavailability in factor VIIa inhibitors.

Vijaykumar D, Rai R, Shaghafi M, Ton T, Torkelson S, Leahy EM, Riggs JR, Hu H, Sprengeler PA, Shrader WD, O'Bryan C, Cabuslay R, Sanford E, Gjerstadt E, Liu L, Sukbuntherng J, Young WB.

Bioorg Med Chem Lett. 2006 Jul 15;16(14):3829-32. Epub 2006 May 2.

PMID:
16650987
27.

Factor VIIa inhibitors: a prodrug strategy to improve oral bioavailability.

Riggs JR, Kolesnikov A, Hendrix J, Young WB, Shrader WD, Vijaykumar D, Stephens R, Liu L, Pan L, Mordenti J, Green MJ, Sukbuntherng J.

Bioorg Med Chem Lett. 2006 Apr 15;16(8):2224-8. Epub 2006 Feb 3.

PMID:
16458507
28.

Small molecule inhibitors of plasma kallikrein.

Young WB, Rai R, Shrader WD, Burgess-Henry J, Hu H, Elrod KC, Sprengeler PA, Katz BA, Sukbuntherng J, Mordenti J.

Bioorg Med Chem Lett. 2006 Apr 1;16(7):2034-6. Epub 2006 Jan 18.

PMID:
16413183
29.

Distribution, metabolism, and excretion of the anti-angiogenic compound SU5416.

Ye C, Sweeny D, Sukbuntherng J, Zhang Q, Tan W, Wong S, Madan A, Ogilvie B, Parkinson A, Antonian L.

Toxicol In Vitro. 2006 Mar;20(2):154-62. Review.

PMID:
16321501
31.

Simultaneous determination of Z-SU5416 and its interconvertible geometric E-isomer in rat plasma by LC/MS/MS.

Zhao Y, Sukbuntherng J, Antonian L.

J Pharm Biomed Anal. 2004 May 28;35(3):513-22.

PMID:
15137976
32.

Proof of target for SU11654: inhibition of KIT phosphorylation in canine mast cell tumors.

Pryer NK, Lee LB, Zadovaskaya R, Yu X, Sukbuntherng J, Cherrington JM, London CA.

Clin Cancer Res. 2003 Nov 15;9(15):5729-34.

33.

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G, Cherrington JM.

Clin Cancer Res. 2003 Jan;9(1):327-37.

34.

Pharmacokinetics and interspecies scaling of a novel VEGF receptor inhibitor, SU5416.

Sukbuntherng J, Cropp G, Hannah A, Wagner GS, Shawver LK, Antonian L.

J Pharm Pharmacol. 2001 Dec;53(12):1629-36.

PMID:
11804393
35.

Simple apparatus for serial blood sampling in rodents permitting simultaneous measurement of locomotor activity as illustrated with cocaine.

Hutchaleelaha A, Sukbuntherng J, Mayersohn M.

J Pharmacol Toxicol Methods. 1997 Feb;37(1):9-14.

PMID:
9086283
36.

Characterization of the properties of cocaine in blood: blood clearance, blood to plasma ratio, and plasma protein binding.

Sukbuntherng J, Martin DK, Pak Y, Mayersohn M.

J Pharm Sci. 1996 Jun;85(6):567-71.

PMID:
8773950
37.
38.
39.

Disposition kinetics of d- and l-amphetamine following intravenous administration of racemic amphetamine to rats.

Hutchaleelaha A, Sukbuntherng J, Chow HH, Mayersohn M.

Drug Metab Dispos. 1994 May-Jun;22(3):406-11.

PMID:
8070317

Supplemental Content

Loading ...
Support Center